Searched for
NDEA
Open source AI: Mission aborted?The open-source LLM mission seems to be losing market share among enterprises but research efforts to democratise open model use continue.- Travelling with buddies? A guide to have fun without being at loggerheads!Travelling with friends can be fun. However, falling out over conflicting plans and bills is also way too common for comfort!
- Can Budget convert India’s demographic dividend into skill dividend?This year’s budget should create clear directives and frameworks for policy implementation and provide a much-required support ecosystem sp...
- USFDA pulls up Mylan for manufacturing violations at Andhra plantIn a warning letter issued to the company's CEO Heather Bresch, the US Food and Drug Administration (USFDA) said inspectors during May 27 t...
- Mylan to invest $1 billion in India on capex in 6 yearsCurrently Mylan has 21 facilities and 15,000 employees working in India.
- USFDA issues warning letter to Lantech Pharma for manufacturing violations at Andhra plantIn a warning letter issued to the company's Managing Director V Prakash Reddy, the USFDA said inspectors during March 6-15 this year found ...
- Hair in one vail, Aurobindo recalls 88k Lidocaine injections from USAccording to a notification put up by the US Drug regulator in its website, these vials were manufactured in India for AuroMedics Pharna LL...
- Aurobindo Pharma, Lupin recall drugs in US marketBesides, Mumbai-based Lupin is also recalling 3,200 bottles of Testosterone Topical solution in the US for issues with the container.
- Torrent Pharma recalls around 2.30 lakh bottles of high BP treatment tablets from USThe tablets were manufactured by Torrent Pharma in its Mehsana facility in India, the report said.
- Aurobindo Pharma USA recalls 80 lots of blood pressure drug from AmericaTo date, Aurobindo Pharma USA Inc has not received any reports of adverse events related to this recall, the release said.
- Aurobindo recalls hypertensive drug in US citing cancer riskScieGen Pharmaceuticals has initiated recall of the finished Irbesartan drug from the market, a separate notification by the FDA said.
Load More
